We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cleantech Building Materials | LSE:CBM | London | Ordinary Share | GB00BV1VRR47 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.875 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Dec 2019 to Dec 2024
DOW JONES NEWSWIRES
Cambrex Corp. (CBM) has received a warning letter from the U.S. Food and Drug Administration related to a March inspection of the company's generic active pharmaceutical ingredient, or API, manufacturing facility in Milan, Italy.
Some of the problems cited in the FDA's letter have already been addressed, the company said. But the FDA could block U.S. entry for products manufactured there. It also could withhold approval of new applications or supplements from the facility.
Cambrex added that it expects to address all of the issues in the time period prescribed by the FDA. The letter only applies to the Milan facility, and is not related to other manufacturing facilities.
The company last month reported second-quarter sales fell 9.8% on currency changes, but earnings tripled on cost cuts.
Shares recently fell nearly 1% to $5.31.
-By Alexandra Scaggs, Dow Jones Newswires; 212-416-2673; alexandra.scaggs@dowjones.com
1 Year Cleantech Chart |
1 Month Cleantech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
